Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Exercise program aims to protect hearts of young cancer survivors

NCT ID NCT05023785

Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a six-month program of supervised exercise, heart risk management, and online support can improve heart and lung fitness in young cancer survivors (ages 18-45) who have mild heart dysfunction. About 336 participants across Canada will be randomly assigned to the program or standard care. The goal is to see if this approach can prevent further heart decline and improve quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 336 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be a PAYA-CS, defined as ≤39 years of age at the time of cancer diagnosis; 2. Be 18-45 years of age at the time of enrolment; 3. Received cancer treatment(s) with known cardiovascular risks (e.g., anthracyclines, trastuzumab, radiotherapy, platinum-based agents, vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors); 4. Be cancer-free at the time of enrollment; 5. Stage B Heart Failure (SBHF) * In patients with availability of pre-treatment imaging: * ≥10% decrease in LVEF at post-treatment compared to pre-treatment * ≥15% decrease in GLS at post-treatment compared to pre-treatment * No pre-treatment imaging: * LVEF ≤53% in women/51% in men * GLS \>-18% * Left ventricular hypertrophy (LV mass/body surface area: \>95 g/m2 for women or \>115 g/m2 for men) * Concentric remodelling (\>0.42 relative wall thickness) * Diastolic dysfunction (≥ grade 1) * BNP ≥35pg/ml or NT-proBNP ≥125pg/ml Exclusion Criteria: 1. Have an absolute or unresolved relative contraindication to exercise according to the American College of Sports Medicine guidelines; 2. Have an untreated physical or mental health concern that precludes safe and effective exercise participation; 3. Have established CVD (excluding mildly reduced LVEF as described above); 4. Be pregnant at time of recruitment; 5. Be currently engaging in frequent high-intensity exercise (\>1 high-intensity exercise session per week); 6. Have substantial barriers to participating, including (1) living too far from study centre or (2) being unable or willing to comply with the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behavior cancer Cardiotoxicity heart failure neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Cardiotoxicity Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Health Network

    RECRUITING

    Toronto, Ontario, M5G2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.